Actively Recruiting
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients
Led by Institut Paoli-Calmettes · Updated on 2025-06-11
100
Participants Needed
1
Research Sites
179 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this interventional study is to learn about the efficacy of first-line chemotherapy with Gemcitabine in metastatic pancreatic adenocarcinoma patients expressing the GemCore signature in their tumor. The main question it aims to answer is to assess efficacy of Gemcitabine (tumor response, survival rate) in the population of patient bearing the GemCore signature. Participants will start the chemotherapy with Gemcitabine as usually performed in standard care of their center. They will consent to a genomic analyze of their tumor to know if it bears the GemCore signature. The center will manage the participant's follow up as usually realized in standard care.
CONDITIONS
Official Title
Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with metastatic pancreatic adenocarcinoma confirmed by histology
- Ineligible for FOLFIRINOX chemotherapy and planned to receive first-line gemcitabine monotherapy
- Tumor sample available with at least 10% tumor cells for GemCore status analysis
- Life expectancy greater than 2 months
- Measurable tumor targets according to RECIST 1.1 criteria
- No previous treatment for metastatic disease
- Age 18 years or older
- Patient agrees to participate in the study
- Affiliated with or beneficiary of a social security system
You will not qualify if you...
- Contraindication to gemcitabine treatment
- Eastern Cooperative Oncology Group (ECOG) performance status of 3 or higher
- In an emergency situation or unable to express non-opposition to participation
- Under legal protection measures such as guardianship, curatorship, or safeguard of justice
- Unable to attend medical follow-up due to geographic, social, or psychological reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut Paoli Calmettes
Marseille, France
Actively Recruiting
Research Team
J
Jihane PAKRADOUNI, Dr
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here